Skip to main content

Additional Advances in Soft Tissue Sarcoma With Brian Rubin, MD, PhD

Oncology Data Advisor® · Additional Advances in Soft Tissue Sarcoma With Brian Rubin, MD, PhD Last year, Brian Rubin, MD, PhD, Chair of Pathology and Laboratory Medicine and the Chief of Diagnostics at the Cleveland Clinic, served as co-chair for i3 Health's continuing medical education (CME)–/nursing continuing professional development (NCPD)–approved virtual tumor board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma, alongside Kathleen Polson, Nurse Practitioner at Da...

Continue reading

Additional Advances in Soft Tissue Sarcoma With Brian Rubin, MD, PhD

Last year, Brian Rubin, MD, PhD, Chair of Pathology and Laboratory Medicine and the Chief of Diagnostics at the Cleveland Clinic, served as co-chair for i3 Health's continuing medical education (CME)–/nursing continuing professional development (NCPD)–approved virtual tumor board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma, alongside Kathleen Polson, Nurse Practitioner at Dana-Farber Cancer Institute, and Shreyaskumar R. Patel, MD, Center Medical Director of the Sarcoma Center ...

Continue reading

Improving Comprehension of Graft-Versus-Host-Disease for Enhanced Patient Outcomes

Recently, i3 Health provided an educational activity that challenged knowledge gaps experienced by clinicians regarding improved patient outcomes in graft-versus-host disease (GVHD).   Graft-versus-host disease is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality. Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver. Chronic GVHD often presents within t...

Continue reading

Addressing Knowledge Gaps in the Treatment of Advanced Endometrial Cancer

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding emerging checkpoint inhibitor–based strategies for advanced endometrial cancer.   Cancer of the uterine corpus is the most common cancer of the female genital tract, with an estimated 67,880 new cases diagnosed and 13,250 deaths annually in the United States. Since more than 90% of cases occur in the endometrium, cancer of the uterine corpus is often referred to as end...

Continue reading

Additional Advances in Advanced Prostate Cancer With Tanya Dorff, MD

Oncology Data Advisor® · Additional Advances in Advanced Prostate Cancer With Tanya Dorff, MD Recently, Tanya Dorff, MD, Division Chief of the Genitourinary Disease Program at City of Hope, served as faculty for i3 Health's CME/NCPD-approved activity, Evolving Treatment Concepts and New Data in Advanced Prostate Cancer. Since recording, a plethora of new data and treatment options have been made available for prostate cancer, as well as additional ongoing and future clinical trials to...

Continue reading

Additional Advances in Advanced Prostate Cancer With Tanya Dorff, MD

Recently, Tanya Dorff, MD, Division Chief of the Genitourinary Disease Program at City of Hope, served as faculty for i3 Health's CME/NCPD-approved activity, Evolving Treatment Concepts and New Data in Advanced Prostate Cancer. Since recording, a plethora of new data and treatment options have been made available for prostate cancer, as well as additional ongoing and future clinical trials to look forward to. In this interview, Dr. Dorff catches us up to speed on these new advancements and share...

Continue reading

Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Ticiana Leal, MD

Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, recorded a continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity titled Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer (NSCLC). With numerous developments in the field occurring since recording the activity, including new FDA approvals and clinical trial results, Dr. Leal sat down wit...

Continue reading

Enhanced Proficiency for Treatment Paradigms in Advanced Hepatocellular Carcinoma

i3 Health recently provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding treatment paradigms in advanced hepatocellular carcinoma (HCC).   Liver cancer is the sixth most common tumor type and the third leading cause of cancer-related death worldwide. The American Cancer Society estimates that in the United States, 41,210 new cases will be diagnosed and 29,380 people will die of the disease this year alone. Hepatocellular carcinoma is the mos...

Continue reading

Assessing Proficiency in Squamous Non–Small Cell Lung Cancer Management

i3 Health recently provided an online continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity that has challenged the health care team's proficiency in managing metastatic squamous non–small cell lung cancer (NSCLC). Lung cancer is the second most common cancer in the United States between both men and women, with the American Cancer Society estimating a total of 238,340 new cases being diagnosed and 127,070 deaths occurring throughout 2023. Appr...

Continue reading

Educational Advancements Made in Treatment of Merkel Cell Carcinoma

i3 Health has provided a continuing medical education/nursing continuing professional development (CME/NCPD)–approved activity, Update on Immunotherapeutic Strategies for Advanced Merkel Cell Carcinoma, that enabled the health care team to acquire significant gains in proficiency and knowledge for treating their patients with Merkel cell carcinoma (MCC). Merkel cell carcinoma is a rare and aggressive neuroendocrine tumor of unknown origin that typically presents in older white and immunocompromi...

Continue reading

Staying Up to Date on Management of Tumor Lysis Syndrome With Amy Goodrich, MSN, RN, CRNP

Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor cell death in which potassium, phosphate, and nucleic acids are released into the bloodstream. The most effective management strategy is prevention; however, despite appropriate prophylactic measures, approximately 3% to 5% of high-risk patients receiving chemotherapy are affected.

In this interview, Amy Goodrich, MSN, RN, CRNP, a Nurse Practitioner and Research Nursing Manager at the Johns Hopkins Kimmel Cancer Center, discusses a recent educational activity she co-led, Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies

Continue reading